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Parathyroid hormone-related peptide (PTHrP) and transforming rowth factor-2 (TGF-o) were found to stimulate proliferation 01’ human lung 
cancer cells (BEN-57). TGF-a stimulated PTMrP secretion from these cells. The polyclonal antisera raised against PTi!rP significantly inhibited 
the growth of BEN-57 cells. and also the proliferation induced by TGF-cc, Treatment of cells ror up to IO days with either a PTHrP reccplor 
antagonist (PTHrP(7-34)) or PTHrP antiserum significantly inhibited the subseyucnl growth ot’ these cells. We suggest that PTHrP muy be a 
componem of a complex uutocrine loop involving TGF-a, 
PTHrP: TGF-a: Lung cancer: Autocrine 
1. INTRODUCTION 
The production of both inhibitory and stimulatory 
growth factors is a likely mechanism leading to the au- 
tocrinc regulation of normal cellular proliferation. 
While these factors are known to bind to specific recep- 
tors the exact manner in which they exert their effect is 
less certain. However, induction of other cellular onco- 
genes, that are either permissive For cell division or that 
trigger it, may be one way in which they act. In addition, 
over-expression oFcertain growth factors may be part 
of the initiation process leading to tumour formation 
VI. 
The recently discovered parathyroid hormone-related 
peptide (PTHrP) has been implicated as the major cause 
of the syndrome of humoral hypercalcaemia of malig- 
nancy [2]. In this condition, exhibited by almost 20% of 
cancer patients, production of PTHrP by turnours leads 
(through the molecule’s parathyroid hormone-like bio- 
activity) to a significantly elevated plasma calcium level, 
so complicating further the clinical management of the 
tumour. While the production of ectopic hormones by 
tumours is not uncommon, it has begun to emerge that 
some of these humoral factors may (in addition to pos- 
sessing systemic hormonal activity) stimulate tumour 
growth in an autocrine manner [3]. 
Expression of PTHrP is not confined to tumour cells, 
having been isolated in a variety of normal human adult 
[4] and foetal tissues [5-71. The role it plays in adult 
physiology is unclear but in the case of the foetus it has 
been suggested that PTI-IrP may be responsible for the 
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maintenance of the foetus-directed transplacental cal- 
cium gradient [S] and, additionally it may play a role as 
a foetal growth factor [‘?I. Although PTI-IrP may possess 
growth factor-like bioactivity, it is uncertain whether it 
exhibits bioactivity similar to transforming rowth fac- 
tor-p (TGF-P) [9,10]. The peptide does, however, mod- 
ulate the effect of TGF-P on DNA synthesis by bone 
cells [l 11. The secretion of PTHrP by a human osteosar- 
coma cell line is enhanced by epidermal growth facto1 
[12] as is secretion by human kerntinocytes [13]. Fur- 
thermore, addition of PTHrP to human keratinocytes 
has been suggested to inhibit proliferation and induce 
terminal differentiation [ 141. 
Human foetal lung is a plentiful source of PTHrP [S], 
as are many cases of carcinoma of the lung [4]. In con- 
trast, nom?nl adult human lung does not appear to 
express the peptide. We report here the results of exper- 
iments designed to investigate whether or not PTHrP 
can function as an autocrine growth factor for a human 
lung cancer cell line (BEN-57), in vitro. 
2. MATERlALS AND METHODS 
PTHrP( l-34) and -(7-34) were obtained from Peninsula Laboralo. 
ries(Mcrscyside, UK). Recombinant human transforminggrowth Tat- 
tot=a (TGF-a) was the gilt of Dr. R. Dcrynck (Gencmcch Inc.. CA, 
USA). 
Polyclonul antisera raised in rabbits against PTllrP( l-34) and .(56- 
S(i) was the girt of Drs. G.V. Segre and H. Juppncr (Massachusclts 
General Hospital, Boston, USA), The specificity and use of these 
antisera in immunocytochcmistry have been characlerised previously 
[61. 
Human lung cancer cells. BEN-57, were obtained from the cell 
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bank, Sir William Dunn School of Pathology (University of Oxford, 
UK). These cells were grown as described previously [I 51 in DMEM/ 
199 medium (I:l) supplemented with glutamine and 2% foetal calf 
serum, 
Human renal ccl1 carcinoma cells (SKRC-I), were provided by Dr. 
N.H. Bander (Memorial SIcan-KcttesinfJCancer Institute. New York, 
USA), and were grown as described previously [IG]. Transformed 
human keratinccytes (SVKII) wcrc supplied by Dr. T. Kamalati (Di- 
vision of Biomedical Sciences, Kings Colle8e. London, UK) and were 
grown as described previously [171. 
2.3. P’fHrP ussy)~ 
A two-site immunoradiomctric assay for PTHrP(l-86) was kindly 
performed by Dr. W. Ratcliff (Queen Elizabeth Hospital. Dirming 
ham, UK) as described previously [18]. 
Cells were maintained in Nunc 75 cm? tissue culture flasks. In 
experiments, cells were seeded at the required ensity in Nunc 24-well 
plates and treated with either pcptides or antisera for the dcsircd lime 
period. Cells were then trypsinized and counted using an Elzone Parti- 
cle Counter, model PC. Statistical significance between control and 
ireated groups was assessed using Student’s r-test. Data arc rcprc- 
scnted as mean -I- S.E.M. 
3. RESULTS 
BEN-S?, SKRC-1 cells and human keratinocytes, are 
known to secrete PTHrP. By adding or removing 
PTHrP from cultures of growing cells the effect of en- 
dogcnously secreted peptide on cell growth was as- 
sessed. 
PTHrP( l-34) was found to be mitogenic for BEN-57 
cells (Fig. l), but this effect was produced only at a 
concentration of 100 nM, and as such considerably in 
excess of that found in culture medium. Twenty-four 
hour conditioned media contained PTHrP at a conccn- 
tration of approximately 65 pM (Fig. 2b). TGF-a was 
mitogenic to BEN-57 cells and stimulated growth at an 
optimal concentration of approximately I pg&tl (Fig. 
2a). To see whether or not TGF-a stimulated PTHrP 
release from BEN-57 cells, cultures were incubated in 
140 
t-9 
- i 
0 130 
+ 
x 
L I 
/ 
3 -+4 
l-4 r) 90 
0 +-T-T-T IO 
-log LPlIHrP] (moles / I). 
Fig. 1. PTHrP(l-34) is mitogcnic to BEN-57 cells but cnly at high 
doses. Cells were seeded at a concentration of 3 x 10 cells per well. 
After I2 b, cells were cultured with medium, either alone or containing 
PTHrP(l-34) at the concentration indicated. The culture media was 
changed aily, and after 3 days the cells were trypeinized and counted. 
(Points represent the mean z SEM; n=4). 
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Fig. 2. Effect of TGF-a on (a) growth of BEN-57 cells. and (b) PTHrP 
secretion by BEN-57 cells, (a) Cells were seeded at a concentration of 
4 x IO” per well. After I2 h, cells were cultured with medium containing 
TCF-a at the concentration i dicated. Media was changed aily and 
after 3 days the cells were trypsinized and counted. (Points rcprcaent 
the mcun 1 SEM: 12=8.) (b) Cells were seeded at a concentration of 
IO x IO per well and 12 h later the culture media was replaced with 
0.5 ml of medium containing TGF-a. at the concentration i dicated. 
After a further 24 h medium was rcmovcd and assayed for PTHrP 
(I-SG). (Points represent the mean f SEM: n=4.) 
the presence of TGF-a for 24 h and the medium subse- 
quently assayed fcr immunoreactive PTHrP. PTHrP 
secretion was stimulated by TGF-a (Fig. 2b) - again at 
an optimal concentration of approximately 1 p&ml. 
Addition of antisera raised against both PTMrP( I- 
34) and -(56-86) was found to significantly inhibit cell 
growth after three days (Fig. 3a shows the mean effect 
of both antisera). This effect did not appear to be a 
non-specific or cytotoxic one as preimmune serum was 
without effect, and addition of the same antisera srirt~u- 
Iut& the growth of transformed human keratinocytes 
(Table I). Furthermore, as Fig. 3b shows, it was possible 
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Fig. 3, Polyclonal PTHrP antisera inhibit the growth of BEN-57 cells. (a) Cells were seeded at 4 x 10J pur well and I2 h later the culture medium 
was changed for one containing antisera raised against either PTHrP(l-34) or -(56-S@. After 48 h cells were trypsinized and counted. (Points 
represent mean of both antisera C SEM; ~8.) (b) Cells wcrc seeded at a concentration of 10 x lo” per well and 12 h later the culture medium was 
replaced with 0.5 ml of medium containing TGF-a at the concentration indicated (open bars), or with a medium containing TGF-cc and 
PTHrP(l-34) antisera t a concentration of l/30 (speckled bars). After 3 days cells were trypsinized and counkd. (Points represent the mean % 
stimulation or inhibition compared to untreated controls ?: SEM; r1=3.) 
to reduce the inhibitory effect of the antisera on BEN-57 
cells by inclusion of TGF-a in the media which, as just 
described, was found to enhance PTHrP secretion and 
cellular proliferation. 
Treatment of cells with the PTHrP receptor antago- 
nist (PTHrP(7-34) for 3 days did inhibit growth, but not 
to the same extent as treatment with antisera. 1 ,uM of 
PTHrP(7-34) inhibited growth by approximately 20%. 
However, long-term treatment of BEN-57 cells, for up 
to 10 days, with either FTHrP(56-86) antisera or 
PTHrP(?-34) markedly inhibited cell growth (Table I). 
When these cells were trypsinized and seeded into cul- 
ture plates in medium without either antagonist or an- 
tisera their subsequent growth was significantly inhib- 
ited (Fig. 4) throughout the following period. There was 
no obvious change in cell morphology following long 
term treatment with either antisera or antagonist. 
4. DISCUSSION 
The data presented inthis study demonstrates, for the 
first time, that PTHrP can modulate the growth of 
human lung cancer cells, possibly in an autocrine man- 
ner. This is suggested by the fact that PTHrP, albeit at 
relatively high concentrations, triggers cell growth, and 
the antibody to PTHrP inhibits proliferation. TGF-a 
stimulates cell proliferation and also, over the same 
dose range, PTHrP secretion. The possibility that TGF- 
cc exerts, in part, its effect on cell proliferation via 
PTHrP is supported by the finding that the antibody to 
PTHrP inhibits this TGF-a induced response. 
It has been realised for a number of years that with- 
drawal of growth factors from some tumour cells results 
in inhibition of growth of these cells and programmed 
cell death, or apoptosis [19-211. Recently, it has been 
demonstrated that removal of interleukin-3 from hemo- 
poietic precursor cells results in cell death as distinct 
from inhibition of proliferation [221. The data presented 
here would suggest ha! PTHrP may be mitogenic to 
BEN-57 cells: it is not certain whether PTHrP protects 
these cells from apoptosis, nor is it known whether it 
stimulates expression of so-called ‘competence genes’ 
such as c-myc, which in turn mediate cell division. What 
is clear, however, is that PTHrP is required for the 
maintained proliferation of BEN-57 cells in vitro. 
The culture medium in which BEN-57 cells prolifer- 
ated for 24 h contained 65 pM PTHrP. If this level of 
PTHrP is sufficient o trigger mitosis then it is reasona- 
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Fig. 4. Treatment of DEN-57 cells with polyclonal PTHrP antisera or 
the PTHrP antagonist PTHrP(l-34) inhibits subsequent cell growlh. 
Cells were seeded at a concentration of 2.0 x IOJ in 3.5 cm2 Petri dishes. 
Aficr I? b, the culture media was replaced with one conlaining no 
additives (3), or with one containing amisera raised against 
PTHrP(!X-8(i) (0) diluted l/20, or with one containing I ,uM 
PTHrP(7-34) (0). Media were changed on ahernatc days over the 
following IO days (or in a separate xperiment with I MM PTHrP(7- 
34) for only 6 days; A). Cells were then trypsinized and re-seeded nt
a conccmration of 3 x IO” per well in 2hwell plates in media lacking 
antisera and antagonist. Cells were counted and the media changed 
4. 6, 7 and 1 I days later. (Points rcprcsenl mean f SEM; r1=3.) 
bie to question the physiological significance of a con- 
centration of 100 nM PTHrP rcquircd to further trigger 
proliferation. One possibility is that since BEN cc!!s 
secrete a PTHrP of at least 108 amino acids, the most 
potent mitogcnic activity may reside within the C-termi- 
nal portion of the molecule rather than in the N-termi- 
nal 34 amino acid fragment used here. 
Cell division was inhibited by treatment with either 
a PTHrP antogonist or PTHrP antisera; this did not 
appear to be a non-specific effect on the part of the 
antisera since it appeared to stimulate the growtll of 
transformed human kcratinocytcs, and the effect could 
be ‘tiratcd out’ by inclusion of TGFa in the medium. 
The fact that PTHrP antisera stimulated the growth of 
human keratinocytes, which secrete PTHrP, would sug- 
gest that the peptide tonically inhibits the growth of 
these cells. The data shown here that PTHrP can stimu- 
late the growth of some cells and inhibit that of otllers 
is similar to tlze effects of TGF-/? which can be both 
inhibitory or stimulatory, depending upon the ccl! type 
studied. The observation of reduced proliferation fol- 
lowing treatment for G or 10 days (Fig. 4) with eitller of 
these agents was surprising but was consistant with a 
previous report of the effect of TGF-p on endothelial 
cells [23], and more recently to the effect of a substance 
P analogue on lung tumor growth [24]. Everard and 
colleagues [24] demonstrated that treatment of various 
small. cell lung cancer cell lines with a substance P ana- 
loguc for as little as 4 h markedly inhibited the subse- 
quent growth of these cells. It is possible that tumor 
cells. if deprived of various critical growth factors, un- 
dergo a form of programmed ifferentiation that may 
or may not end in apoptosis. Antibodies to born&sin 
[25], TGF-a [26] and the oncogene product neu [27] have 
been shown to inhibit tumour growth both in vitro and 
in vivo. Immunotherapy, utilizing antisera raised 
against various critical growth factors, is of potentially 
great value in the treatment of cancer and a clinical trial 
using antibodies to bombcsin has been undertaken [28]. 
WC have demonstrated here that ‘secretion’ of PTHrP 
by BEN-57 cells is enhanced by treatment with TGF-(x 
which also stimulates cc!! growth. This observation, and 
those of others [!3,14], would suggest that PTHrP may 
form part of a complex growth factor ‘autocrinc loop’ 
such as has been suggested to exist for TGF-p and 
platelet derived growth factor [29]. The control of cellu- 
lar differentiation and proliferation remains, for the 
most part, a mystery. While TGF-j3 has been sugpstcd 
to be the primary differentiation inducing factor in 
serum for normal human bronchial cpithclia! cells [30], 
the picture of cell division seems more complicated as 
more growth-like factors, such as PTHrP, arc discov- 
ered. We have demonstrated here that PTHrP, whose 
role in the aetiology of human lung cancer was consid- 
ered to be confined to the systemic induction of hypcr- 
calcaemia is, in addition, a factor modulating the prolif- 
Table I 
PTHrP antiserum has differen effects on proliferaGon 
Treauncnt 
Cell line 
Aitriseru 
SKRC-I 
SVKl4 
BEN.57” 
BEN-57” 
87.ooo 35,ooo 
85,000 l40.000 
I40,MH) 87.000 
1,600.ooO 360,ooo 
Armgotrbt 
BEN-57’ 700,000 270,000 
BEN-57” 1.6oWOO 400,ooo 
SKHC-I cells were seeded at 3 x IO’ cells per well and lrcaled for 2 
days with antisera raised against PTHrP(I-34). SVKl4 cells were 
seeded ~1 4 x IO’ cells per well and treated for 2 days with antisera 
raised againa PTHrP( l-34). BEN-57 cells were treated in four differ- 
ent ways, and these are designated BEN-57” through to BEN-57d. In 
each case the CUIWC medium was replaced every 2 days. BEN-57”: 
cells were seeded at a concentration of 4 x IOJ per well and trcald for 
2 days whh antisera raised against PTHrP(l-34). BEN-57b: CCIIS wcrc 
seeded at a concentraGon of 2 x 10’ per Petri dish and treated with 
antisera raised against PTHrP(56-86) for lOdays. BEN-57’: c& were 
seeded at a concentration of 2 x IO5 per Petri dish. They were then 
treated with ihc PTHrP receptor antagonist PTHrP(7-34) for 6 days. 
BENJ7$ cells were seeded al a concentration of2 x IO5 per Pcrri dish. 
They were then treated with ihc PTHrP recqtor anIagonis1 PTHrP 
(7-34) for 10 days. The dala shown in lhe table arc the numbers of 
cells per well from a single cxperimcnt, and are rcprcselllnlive Of 4 
expcrimcnts. 
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eration of human lung cancer cells. If antibodies and 
antagonists to this factor prove to have a similar effect 
in viva they may have an important role in the therapy 
of some PTHrP producing tumours. 
rlc~no~~,(c~~orrenls: W  aregrateful to Mr. J. Gibbs for expert echni- 
cal assistance, 
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